Karuppiah Kannan, associate director at Takeda Pharmaceuticals, talks about the progress made in treating myeloma and where the field is going in the future.
Karuppiah Kannan, associate director at Takeda Pharmaceuticals, talks about the progress made in treating myeloma and where the field is going in the future.
About a decade ago, Kannan says that a myeloma diagnosis was like a death sentence, with low five- and ten-year survival rates. Now, advances in medicine are allowing people with the disease to live longer, more normal lives, but work still needs to be done to find a cure.
TODAY Contributor Undergoes Breast Reconstruction, Arizona Rep. Finishes Cancer Treatment and More
July 12th 2024From a TODAY contributor opening up about breast reconstruction surgery to Arizona rep. Raúl Grijalva completing cancer treatment, here’s what’s going on in the oncology space this week.
Read More